Format

Send to

Choose Destination
Vaccine. 2016 Mar 14;34(12):1452-8. doi: 10.1016/j.vaccine.2016.01.064. Epub 2016 Feb 10.

Preclinical dose-ranging studies of a novel dry powder norovirus vaccine formulation.

Author information

1
Research and Development Department, Nanotherapeutics, Inc., Alachua, FL, United States.
2
Toxicology Department, Battelle Memorial Institute, West Jefferson, OH, United States.
3
Battelle Eastern Science and Technology Center, Aberdeen, MD, United States.
4
Research and Development Department, Nanotherapeutics, Inc., Alachua, FL, United States. Electronic address: rcobb@nanotherapeutics.com.

Abstract

Norovirus is the primary cause of viral gastroenteritis in humans with multiple genotypes currently circulating worldwide. The development of a successful norovirus vaccine is contingent on its ability to induce both systemic and mucosal antibody responses against a wide range of norovirus genotypes. Norovirus virus-like particles (VLPs) are known to elicit systemic and mucosal immune responses when delivered intranasally. Incorporation of these VLPs into an intranasal powder vaccine offers the advantage of simplicity and induction of neutralizing systemic and mucosal antibodies. Nasal immunization, which provides the advantage of ease of administration and a mucosal delivery mechanism, faces the real issue of limited nasal residence time due to mucociliary clearance. Herein, we describe a novel dry powder (GelVac™) formulation of GI or GII.4 norovirus VLPs, two dominant circulating genotypes, to identify the optimal antigen dosages based on systemic and mucosal immune responses in guinea pigs. Systemic and mucosal immunogenicity of each of the VLPs was observed in a dose-dependent manner. In addition, a boosting effect was observed after the second dosing of each VLP antigen. With the GelVac™ formulation, a total antigen dose of ≥ 15 μg was determined to be the maximally immunogenic dose for both GI and GII.4 norovirus VLPs based on evaluation for 56 days. Taken together, these results indicate that norovirus VLPs could be used as potential vaccine candidates without using an immunostimulatory adjuvant and provide a basis for the development of a GelVac™ bivalent GI/GII.4 norovirus VLP vaccine.

KEYWORDS:

Guinea Pigs; Intranasal; Norovirus; Vaccine; Virus-like Particles

PMID:
26873053
PMCID:
PMC4775331
DOI:
10.1016/j.vaccine.2016.01.064
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center